Plain-English translation of NCT07051603 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called designed to help treat high blood pressure. Researchers want to understand how safe this medication is, how your body processes it, and how it affects blood pressure. The study will enroll 82 healthy volunteers and test the medication in three different phases to find the right dose.
High blood pressure affects millions of people worldwide, and doctors are always looking for new, safer, and more effective treatment options. This trial helps researchers understand whether this new treatment could become a helpful option for patients who need better blood pressure control.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic multiple times to take the study medication (or placebo) in carefully controlled doses, starting with a single dose and then moving to multiple doses over time. Each visit involves blood tests, heart monitoring, and blood pressure checks. One part of the study tests how food affects the medication, so you may take doses with and without eating. The entire process is designed to be safe—doctors monitor you closely throughout.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Enrollment target
~82 participants
Started
June 2025
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chongyuan Xu, Ph.D.
Nanfang Hospital, Southern Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.